• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Pseudo-acute kidney injury secondary to tepotinib.

作者信息

Wijtvliet Veerle, Roosens Laurence, De Bondt Charlotte, Janssens Annelies, Abramowicz Daniel

机构信息

Department of Nephrology and Hypertension, Antwerp University Hospital, Antwerp, Belgium.

Laboratory of Experimental Medicine and Pediatrics and member of the Infla-Med Centre of Excellence, University of Antwerp, Antwerp, Belgium.

出版信息

Clin Kidney J. 2022 Aug 1;16(4):760-761. doi: 10.1093/ckj/sfac180. eCollection 2023 Apr.

DOI:10.1093/ckj/sfac180
PMID:37007692
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10061424/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb59/10061424/aea2f7be9d03/sfac180fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb59/10061424/aea2f7be9d03/sfac180fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb59/10061424/aea2f7be9d03/sfac180fig1.jpg

相似文献

1
Pseudo-acute kidney injury secondary to tepotinib.特泊替尼继发的假性急性肾损伤
Clin Kidney J. 2022 Aug 1;16(4):760-761. doi: 10.1093/ckj/sfac180. eCollection 2023 Apr.
2
The selective c-Met inhibitor tepotinib can overcome epidermal growth factor receptor inhibitor resistance mediated by aberrant c-Met activation in NSCLC models.选择性c-Met抑制剂替泊替尼可克服非小细胞肺癌模型中由异常c-Met激活介导的表皮生长因子受体抑制剂耐药性。
Am J Cancer Res. 2017 Apr 1;7(4):962-972. eCollection 2017.
3
Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells.特泊替尼逆转 ABCB1 介导的癌细胞多药耐药性。
Biochem Pharmacol. 2019 Aug;166:120-127. doi: 10.1016/j.bcp.2019.05.015. Epub 2019 May 9.
4
First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors.首个人体 I 期试验评估选择性 MET 抑制剂特泊替尼治疗晚期实体瘤患者的疗效。
Clin Cancer Res. 2020 Mar 15;26(6):1237-1246. doi: 10.1158/1078-0432.CCR-19-2860. Epub 2019 Dec 10.
5
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.特泊替尼联合吉非替尼治疗既往 EGFR 抑制剂治疗后出现 MET 过表达或扩增的 EGFR 突变型非小细胞肺癌患者：一项开放标签、Ib/II 期、多中心、随机试验（INSIGHT 研究）。
Lancet Respir Med. 2020 Nov;8(11):1132-1143. doi: 10.1016/S2213-2600(20)30154-5. Epub 2020 May 29.
6
MET inhibitor tepotinib antagonizes multidrug resistance mediated by ABCG2 transporter: and study.MET抑制剂替泊替尼可拮抗由ABCG2转运蛋白介导的多药耐药性：一项研究。
Acta Pharm Sin B. 2022 May;12(5):2609-2618. doi: 10.1016/j.apsb.2021.12.018. Epub 2021 Dec 30.
7
Responses to the Tepotinib in Gastric Cancers with MET Amplification or MET Exon 14 Skipping Mutations and High Expression of Both PD-L1 and CD44.在具有MET扩增或MET外显子14跳跃突变且PD-L1和CD44均高表达的胃癌中对替泊替尼的反应。
Cancers (Basel). 2022 Jul 15;14(14):3444. doi: 10.3390/cancers14143444.
8
Tepotinib hydrochloride for the treatment of non-small cell lung cancer.盐酸特泊替尼治疗非小细胞肺癌。
Drugs Today (Barc). 2021 Apr;57(4):265-275. doi: 10.1358/dot.2021.57.4.3238323.
9
Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression.Tepotinib 对比索拉非尼治疗 MET 过表达的亚洲晚期肝细胞癌患者的随机 1b/2 期试验。
Br J Cancer. 2021 Jul;125(2):200-208. doi: 10.1038/s41416-021-01380-3. Epub 2021 May 10.
10
Budget impact of tepotinib in the treatment of adult patients with metastatic non-small cell lung cancer harboring ex14 skipping alterations in the United States.替泊替尼在美国治疗携带外显子14跳跃改变的转移性非小细胞肺癌成年患者中的预算影响
J Med Econ. 2021 Jan-Dec;24(1):816-827. doi: 10.1080/13696998.2021.1942017.

引用本文的文献

1
Acute kidney injury: pathogenesis and therapeutic interventions.急性肾损伤：发病机制与治疗干预
Mol Biomed. 2025 Sep 5;6(1):61. doi: 10.1186/s43556-025-00293-4.
2
Comprehensive management of MET tyrosine kinase inhibitor-induced peripheral edema in patients with -altered non-small-cell lung cancer: a narrative review.MET酪氨酸激酶抑制剂引起的非小细胞肺癌患者外周水肿的综合管理：一项叙述性综述
Transl Lung Cancer Res. 2025 Apr 30;14(4):1482-1495. doi: 10.21037/tlcr-24-866. Epub 2025 Apr 17.
3
Kidney Injury in Patient with Non-small-cell Lung Cancer Receiving Tepotinib.

本文引用的文献

1
Capmatinib-Induced Pseudo-Acute Kidney Injury: A Case Report.卡马替尼诱导的假性急性肾损伤：一例报告。
Am J Kidney Dis. 2022 Jan;79(1):120-124. doi: 10.1053/j.ajkd.2021.04.009. Epub 2021 Jun 9.
2
Exon 14 Skipping Mutations in Non-Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations.非小细胞肺癌中外显子14跳跃突变：生物学、临床结局及检测考量概述
JCO Precis Oncol. 2021 Apr 13;5. doi: 10.1200/PO.20.00516. eCollection 2021.
接受替泊替尼治疗的非小细胞肺癌患者的肾损伤
Intern Med. 2025 Jul 1;64(13):2019-2023. doi: 10.2169/internalmedicine.4488-24. Epub 2024 Dec 5.
4
Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study.来自 II 期 VISION 研究的 MET 外显子 14 跳跃 NSCLC 日本患者中 tepotinib 的长期经验。
Cancer Sci. 2024 Apr;115(4):1296-1305. doi: 10.1111/cas.16107. Epub 2024 Feb 25.
5
Capmatinib-Associated Pseudoacute Kidney Injury in Nonsmall Cell Lung Cancer.卡马替尼相关的非小细胞肺癌假性急性肾损伤
Kidney Int Rep. 2023 Aug 28;8(11):2482-2485. doi: 10.1016/j.ekir.2023.08.032. eCollection 2023 Nov.
6
A marked elevation in serum creatinine/cystatin C ratio may indicate pseudo-acute kidney injury due to urinary ascites: a case report and literature review.血清肌酐/胱抑素 C 比值显著升高可能提示尿性腹水引起的假性急性肾损伤：病例报告及文献复习。
BMC Nephrol. 2023 Aug 21;24(1):243. doi: 10.1186/s12882-023-03289-w.
7
Pseudo-AKI associated with targeted anti-cancer agents-the truth is in the eye of the filtration marker.与靶向抗癌药物相关的假性急性肾损伤——真相存在于滤过标志物之中。
Clin Kidney J. 2023 Jan 16;16(4):603-610. doi: 10.1093/ckj/sfad011. eCollection 2023 Apr.
8
The Preclinical Pharmacology of Tepotinib-A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations.替泊替尼的临床前药理学——一种对携带有 MET 改变的肿瘤具有活性的高度选择性 MET 抑制剂。
Mol Cancer Ther. 2023 Jul 5;22(7):833-843. doi: 10.1158/1535-7163.MCT-22-0537.